Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug
Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug — latest biopharma news.
Alzheon
Private
Clinical-stage biopharma developing oral valiltramiprosate for Alzheimer disease treatment, targeting APOE4 patients
Company Info
Sector:Small Molecule Pharma
Headquarters:Framingham, Massachusetts, United States
Founded:2013
Website:alzheon.com/
Upcoming Milestones & Key Dates
2026
Clinical
Phase 3 data readout expected